Introduction
In Europe, neuroborreliosis (NB) is the most common manifestation of disseminated borreliosis, occurring in 14-34 % of all cases with borreliosis [1] [2] [3] . The clinical course of NB is highly variable. In most patients antibiotic therapy leads to full recovery, but some patients experience residual or recurrent symptoms even after treatment [4] [5] [6] [7] [8] .
Jönköping County, with an area of 10,475 km 2 and located in the south-east of Sweden (Figure 1 ), is known to be endemic of borreliosis. In December 2005, the county had 330,179
inhabitants. The prevalence of Borrelia infected Ixodes ticks varies between 10-20% [9, 10] .
The incidence of human borreliosis in Jönköping County was reported to be 60 cases/100,000
inhabitants/year in 1992-93 [1] . Out of these, 10/100,000/year were considered to be NB.
The aims of this retrospective study were to 1) monitor the incidence of NB during 2000-2005, 2) study how NB symptoms relate to age, 3) to identify cases with antibodies in cerebrospinal fluid (CSF) but not in serum at diagnosis, 4) search for possible clinical or laboratory markers associated with the risk of developing long-lasting post-treatment symptoms, and 5) address some economic aspects of NB in terms of cost for health care and social benefits [11] .
Materials and methods

Study population and case definitions
The population studied comprised all the inhabitants in Jönköping County, from 2000 through 2005. Inclusion criteria were clearly positive CSF Borrelia-specific antibody levels (optical density (OD) >0.40 for both IgG and IgM) or borderline levels (IgG: OD 0.19-0.39 and IgM:
OD 0.16-0.39), n=157. All patients had pleocytosis in the CSF, defined as >5 mononuclear cells (MNC)/ L, except for four cases who had positive or borderline Borrelia-specific CSFIgG, positive Borrelia-specific IgG-index (according to either one or both of the Borreliaspecific IgG-index calculation methods described below), and symptoms consistent with active NB. All four patients had a long history of illness (36 weeks to several years). One of them responded to antibiotic treatment, two only partially and one did not get any treatment.
Seven of the 157 patients were excluded due to other obvious diagnoses (e.g. normal pressure hydrocephalus, cerebellar infarction or Varicella encephalitis) and/or absence of pleocytosis.
In these seven cases the anti-Borrelia CSF antibodies were considered to be an indication of a previous NB infection or IgM cross-reactivity to another pathogen (e.g. Varicella). The number of patients included was 150, all of whom had elevated Borrelia-specific antibodies (IgG and/or IgM) in CSF and pleocytosis, except in the four cases mentioned above ( Figure   2 ). 
Laboratory methods
Results
Number of cases/year
During the study period 2000-2005, the annual number of NB cases, verified by CSF analysis, increased from 16 to 32 cases a year (5 to 10/100,000 inhabitants/year) ( Figure 3 ). Ninetythree patients (62%) were men and 57 (38%) were women. The median age was 18 years, with a range from 3-87 years (figure 3).
Clinical and laboratory findings prior to treatment
The reported symptoms and their frequencies are presented in Table 1 . Facial palsy, neck pain, fever and fatigue were more common in patients under the age of 40 (p=0.0001-0.031).
Patients over 40 reported muscle and joint pain, radiating pain, parestesias, vertigo and concentration problems more often than patients under 40 (p=0.0001-0.003). Patients under 40 had shorter duration of symptoms prior to diagnosis than patients over 40 (p<0.0001). A tick bite had been noticed by 32% of the patients, and 24% had an erythema migrans (EM).
CSF pleocytosis was dominated by MNC (median 164 cells/ L, range 0-1380). Increased levels of Borrelia-antibodies were found in CSF but not in serum in 25 (17%) of the patients at the time of diagnosis. These patients had a median duration of symptoms of three weeks (range one day-eight weeks). CSF-albumin/S-albumin ratio, as an indicator of blood-brain barrier (BBB) damage, was elevated in 80% of the patients. CSF-lactate was elevated in 55%
(range 1.3-3.9 mmol/L), and CSF-glucose was low in 9% (range 1.9-8.2 mmol/L). Patients under the age of 40 had higher cell counts in CSF than those over 40 (p<0.0001).
In general, no abnormalities were found in other routine blood laboratory parameters, e.g.
blood cell count, creatinine, electrolytes, aminotransferases, alcalic phosphatase, bilirubine or lactate dehydrogenase. C-reactive protein was elevated (>10 mg/L) in 6 of 99 analyzed patients and white blood cell count was elevated (8.8 x 10 9 /L) in 26 of 98 patients. There were no significant differences between men and women regarding laboratory parameters or duration of illness before diagnosis.
All four patients with Borrelia-specific IgG in CSF and positive Borrelia-specific IgG-index but no pleocytosis had a long history of illness (median 64 weeks, range 36 weeks-six years).
They most frequently reported muscle and joint pain, parestesia, vertigo and concentration problems. Interestingly, the highest Borrelia-specific IgG-indices were found among these four patients (range 2.4-13.1).
Fatigue, fever >38 o C, headache, facial palsy, neck pain and muscle and joint pain were most frequently reported in patients with the most pronounced pleocytosis (CSF cell count >284/ L, the upper quartile), which also correlated with age <40. This group had also significantly higher CSF-albumin (p<0.0001), CSF-albumin/S-albumin ratio (p<0.0001) and CSF-lactate (p=0.001) as well as lower CSF-glucose (p=0.001).
Patients were treated with oral doxycycline (63%), intravenous ceftriaxone (25%), benzylpenicilline (9%) or cefuroxime (1%) for 10-21 days, median 14 days.
Follow-up
At follow-up, 106 patients had completely recovered, but 44 still had symptoms at the last visit. The 106 patients where the clinical course until recovery was clearly documented were classified according to the duration of symptoms post-treatment (Table 2 ). Significant differences in age distributions were found between all the groups, except when comparing group B versus group C. Higher age was associated with longer duration of symptoms. The acute phase symptoms are presented in Table 3 . The only laboratory parameter in the acute phase that differed significantly between the groups was Borrelia-specific CSF-IgG, which was highest in group D. No significant differences were found between the groups regarding type of antibiotic treatment or duration of treatment.
Economic aspects
The total health care cost for the patients in the study group was estimated to 500,000 EUR.
The number of visits to a physician in an out-patient department was 490, the cost of which was estimated to 130,000 EUR. The number of out-patient visits per individual varied between 0 and 10 (median 3), and 79 patients (53%) were hospitalized, median 5 days (range one to 60). The total number of days in hospital generated by the entire study group was 603. ceftriaxone-days were registered, resulting in an estimated cost of 38,000 EUR.
Of the adult patients aged 16-64 years, 26 (51%) received sickness benefits from the Social Insurance Agency (range 4-528 days, median 32 days). The mean cost for sickness benefits was 4,600 EUR/patient. Temporary parental benefits were disbursed to the parents of 39 (51%) of the children (range 0.25-19 days, median 5 days). The estimated total cost for social benefits was 134,000 EUR (2,000 EUR/patient).
Discussion
The number of NB cases verified by CSF analysis increased from 5 to 10/100,000 inhabitants/year during the years 2000-2005 in Jönköping County. The number of NB cases during the first part of the study period was 5-6/100,000 inhabitants, which is about half as many as reported earlier [1] . This discrepancy can be explained by the fact that we only included cases verified by CSF analysis, whereas Berglund et al. included patients diagnosed with NB based on either CSF findings or clinical symptoms and Borrelia antibodies in serum.
There are probably a number of patients who during this study period were treated with antibiotics for a suspected NB infection, in whom the diagnosis was based on symptoms and
Borrelia-specific antibodies in serum. The true number of NB cases in the county can thus be assumed to be even higher than 10/100,000 inhabitants/year. Data on clinical presentation of NB, age and sex distribution, laboratory findings and the frequency of observed tick bites and EM, are mainly in line with earlier observations [19] [20] [21] [22] .
However, some particularly interesting findings should be pointed out. As many as 80% of the patients had an elevated CSF-/S-albumin ratio, as an indicator of impairment of the BBB.
The highest IgG-indeces were found among the four patients with the longest duration of symptoms prior to treatment (9-78 months). These four patients had no pleocytosis, although it can not be excluded that an earlier pleocytosis had normalized by the time of the lumbar puncture, probably reflecting the natural course of the disease. They reported mainly unspecific symptoms.
Patients with a CSF MNC count >284 cells/ L (the upper quartile) most frequently reported symptoms of meningitis and distinct symptoms like facial palsy and fever. They also had the shortest median duration of symptoms before treatment. Patients under the age of 40 had significantly higher MNC count in CSF than patients over 40. The risk of developing longlasting post-treatment symptoms increased with age. One could speculate that young individuals can mobilize a strong and rapid inflammatory response to the Borrelia infection, giving them more distinct clinical symptoms, which in turn leads to an early diagnosis and treatment, as well as effective elimination of bacteria. Accordingly, a strong initial inflammatory response has previously been demonstrated to be associated with good prognosis in borreliosis [23] [24] [25] [26] [27] . In contrast, older patients show a less pronounced inflammatory response and they often present with more vague symptoms, which might delay the diagnosis and treatment.
Our findings emphasize the importance of CSF analysis for the NB diagnosis, since 17% of the patients presented with elevated levels of Borrelia-specific antibodies in CSF but not in serum. Repeated sampling was not performed in our study, so we can not establish if these patients developed antibodies in serum later on. However, without a diagnostic lumbar puncture, these patients might have been misdiagnosed. Earlier studies [7] , as well as our data, further indicate that the duration of symptoms before treatment might be of importance for the clinical outcome.
Symptoms lasting more than six months post-treatment were reported by 13% of the patients (14/106 There are of course limitations to this retrospective study, such as a presumable bias both in reported and documented symptoms. Data on time to recovery were not possible to obtain from all patients. However, the data were available in a substantial number of cases and, furthermore, our data are in line with previous prospective studies [1] , thus supporting the accuracy of the results.
In conclusion, the number of NB cases seems to have increased in 
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